Ronald Goldwater

973 total citations
32 papers, 708 citations indexed

About

Ronald Goldwater is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Ronald Goldwater has authored 32 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Pharmacology and 6 papers in Oncology. Recurrent topics in Ronald Goldwater's work include Receptor Mechanisms and Signaling (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ronald Goldwater is often cited by papers focused on Receptor Mechanisms and Signaling (4 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Ronald Goldwater collaborates with scholars based in United States, United Kingdom and Sweden. Ronald Goldwater's co-authors include Donna Kowalski, David Han, Atsunori Kaibara, James J. Keirns, Michael DeMicco, Ellen Chung, Anna Persson, Thomas Marbury, Richard E. Nettles and M. Rodríguez‐Torres and has published in prestigious journals such as Circulation, Blood and Gastroenterology.

In The Last Decade

Ronald Goldwater

30 papers receiving 695 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronald Goldwater United States 12 190 154 145 136 118 32 708
Jonathan Q. Tran United States 19 169 0.9× 33 0.2× 131 0.9× 287 2.1× 170 1.4× 43 1.0k
Kentaro Watanabe Japan 17 92 0.5× 135 0.9× 37 0.3× 369 2.7× 193 1.6× 77 1.2k
Qing Pang China 22 407 2.1× 93 0.6× 365 2.5× 314 2.3× 32 0.3× 67 1.3k
Anna Garmpi Greece 17 178 0.9× 49 0.3× 131 0.9× 529 3.9× 39 0.3× 83 1.2k
Katryn N. Furuya United States 17 174 0.9× 49 0.3× 149 1.0× 135 1.0× 35 0.3× 39 695
Erica Sparkenbaugh United States 21 124 0.7× 109 0.7× 78 0.5× 467 3.4× 56 0.5× 43 1.5k
Giridhar Tirucherai United States 17 369 1.9× 137 0.9× 108 0.7× 416 3.1× 20 0.2× 41 1.3k
Cristian Loretelli Italy 20 135 0.7× 83 0.5× 131 0.9× 570 4.2× 27 0.2× 65 1.4k
Hiromitsu Yokota Japan 20 109 0.6× 163 1.1× 67 0.5× 579 4.3× 96 0.8× 60 1.1k
Keizo Kagawa Japan 20 360 1.9× 189 1.2× 331 2.3× 300 2.2× 26 0.2× 70 1.1k

Countries citing papers authored by Ronald Goldwater

Since Specialization
Citations

This map shows the geographic impact of Ronald Goldwater's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald Goldwater with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald Goldwater more than expected).

Fields of papers citing papers by Ronald Goldwater

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald Goldwater. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald Goldwater. The network helps show where Ronald Goldwater may publish in the future.

Co-authorship network of co-authors of Ronald Goldwater

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald Goldwater. A scholar is included among the top collaborators of Ronald Goldwater based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald Goldwater. Ronald Goldwater is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Douros, Jonathan D., Ronald Goldwater, Ann Maria Kruse Hansen, et al.. (2025). A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans. Molecular Metabolism. 96. 102129–102129. 6 indexed citations
2.
Zhou, Xiaohong, Nicola Ferrari, Zhi Liu, et al.. (2025). A phase 1 study evaluating the safety, tolerability, and pharmacokinetics of the porcupine inhibitor, AZD5055. iScience. 28(6). 112602–112602.
3.
Friedrichsen, Martin, Lars Endahl, Frederik Flindt Kreiner, et al.. (2023). Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity. Molecular Metabolism. 78. 101801–101801. 27 indexed citations
4.
So, Karen, et al.. (2022). A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib. Clinical Therapeutics. 44(4). 565–576. 1 indexed citations
5.
Blauwet, Mary Beth, et al.. (2022). A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects. Journal of Psychopharmacology. 36(6). 756–767. 11 indexed citations
6.
Dota, Corina, Weili Yan, Remy B. Verheijen, et al.. (2021). A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval. Clinical Pharmacology in Drug Development. 10(5). 521–534. 5 indexed citations
7.
Bonate, Peter L., Charles Van Sant, Erin C. Zook, et al.. (2020). Pharmacokinetics and Immunogenicity of ASP0113 in CMV‐Seronegative Dialysis Patients and CMV‐Seronegative and ‐Seropositive Healthy Subjects. Clinical Pharmacology in Drug Development. 9(4). 444–455. 3 indexed citations
8.
So, Karen, et al.. (2020). CTNI-09. A PHASE I HEALTHY VOLUNTEER STUDY ON THE RELATIVE BIOAVAILABILITY AND FOOD EFFECT OF CAPSULE AND GRANULE FORMULATIONS OF SELUMETINIB. Neuro-Oncology. 22(Supplement_2). ii43–ii43. 1 indexed citations
9.
Goldwater, Ronald, Azra Hussaini, Bill Bosch, & Paul R. Nemeth. (2017). Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies. Clinical Pharmacokinetics. 56(7). 803–813. 25 indexed citations
10.
Cebers, Gvido, Robert Alexander, Samantha Budd Haeberlein, et al.. (2016). AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease. Journal of Alzheimer s Disease. 55(3). 1039–1053. 68 indexed citations
11.
12.
Yamazaki, Takao, Amit Desai, Ronald Goldwater, et al.. (2016). Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects. Clinical Pharmacology in Drug Development. 6(1). 54–65. 33 indexed citations
13.
14.
Goldwater, Ronald, James J. Keirns, R. First, et al.. (2013). A Phase 1, Randomized Ascending Single-Dose Study of Antagonist Anti-Human CD40 ASKP1240 in Healthy Subjects. American Journal of Transplantation. 13(4). 1040–1046. 58 indexed citations
15.
Edwards, Eric S., et al.. (2013). Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Annals of Allergy Asthma & Immunology. 111(2). 132–137. 25 indexed citations
16.
17.
Malík, Marek, E. Marcel van Gelderen, Donna Kowalski, et al.. (2012). Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study. Clinical Pharmacology & Therapeutics. 92(6). 696–706. 112 indexed citations
18.
Nettles, Richard E., Min Gao, Marc Bifano, et al.. (2010). Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 54(6). 1956–1965. 141 indexed citations
19.
Goldwater, Ronald, et al.. (1999). Phase 1, randomized, parallel, placebo‐controlled, safety, tolerance and pharmacokinetic study of multiple dose of IY‐81149 in fasting male volunteers. Clinical Pharmacology & Therapeutics. 65(2). 126–126. 5 indexed citations
20.
Palmour, Roberta M., et al.. (1990). Characterization of a Primate Model of Hypertension. American Journal of Hypertension. 3(1). 27–32. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan Q. Tran Breakdown of academic impact, for papers by Kentaro Watanabe Breakdown of academic impact, for papers by Qing Pang Breakdown of academic impact, for papers by Anna Garmpi Breakdown of academic impact, for papers by Katryn N. Furuya Breakdown of academic impact, for papers by Erica Sparkenbaugh Breakdown of academic impact, for papers by Giridhar Tirucherai Breakdown of academic impact, for papers by Cristian Loretelli Breakdown of academic impact, for papers by Hiromitsu Yokota Breakdown of academic impact, for papers by Keizo Kagawa
Rankless by CCL
2026